Company intelligence / Profile preview

Healcerion

Seoul, Seoul, South Koreahealcerion.com ↗

Ownership: Private
Employees: ~17
Development stage: Commercial

Overview

Healcerion has commercialized the SONON series, the world’s first mobile-based portable wireless ultrasound devices. These are used in a variety of clinical and remote settings for diagnostic imaging. Clinical studies have demonstrated that their wireless handheld ultrasounds provide high-quality images comparable to standard systems and can be used effectively in point-of-care applications. Published literature supports their use in musculoskeletal, cardiovascular, maternal-fetal medicine, and general diagnostic applications. No drug or therapeutic clinical pipeline; focus on medical imaging technology.

Therapeutic areas: Other
Modalities: DevicePortable ultrasound
Industry: Medical Imaging

Partnerships

No major pharmaceutical or biotech partnerships listed; distribution partners likely but not specified.

Beyond the preview

Go deeper on Healcerion.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Healcerion.

Explore the full profile